The involvement of follistatin-like protein 1 in osteoarthritis by elevating NF-κB-mediated inflammatory cytokines and enhancing fibroblast like synoviocyte proliferation by unknown
Ni et al. Arthritis Research & Therapy  (2015) 17:91 
DOI 10.1186/s13075-015-0605-6RESEARCH ARTICLE Open AccessThe involvement of follistatin-like protein 1 in
osteoarthritis by elevating NF-κB-mediated
inflammatory cytokines and enhancing fibroblast
like synoviocyte proliferation
Su Ni1,2†, Kaisong Miao1,2†, Xianju Zhou3, Nanwei Xu1, Chenkai Li1,2, Ruixia Zhu1, Rongbin Sun1 and Yuji Wang1,2*Abstract
Introduction: Our previous work has revealed that expression of follistatin-like protein 1 (FSTL1) is elevated in the
synovial tissues from osteoarthritis (OA) patients. The aim of this study was to elucidate the underlying molecular
mechanisms by which FSTL1 plays a role in the pathogenesis of OA.
Methods: Cultured fibroblast-like synoviocytes (FLSs) from synovial tissues of OA patients were stimulated with
human recombinant FSTL1, and then the expression of inflammatory cytokines in FLS and their concentrations in
the cell supernatants were measured by real-time polymerase chain reaction (PCR) and enzyme-linked immunosorbent
assay (ELISA), respectively. Nuclear factor kappa B (NF-κB) activation was examined by western blot and chromatin
immunoprecipitation (ChIP) assay at the p65 binding site. Finally, the proliferation of FLSs and the expression level of
the proliferation-related tumor suppressors (p53 and p21) were determined by MTS assay kit and western blot in the
presence or absence of FSTL1, respectively.
Results: FSTL1 remarkably promoted expression levels of several inflammatory cytokines (tumor necrosis factor alpha
(TNF-α), interleukin-1β (IL-1β) and interleukin-6 (IL-6)) in vitro. Western blot analysis showed that FSTL1 activated the
inflammatory-related NF-κB signaling pathway, as validated by ChIP assay detecting p65-binding level on the cytokine
promoter region. Moreover, FSTL1 promoted the proliferation of OA FLS by downregulating the expression of p53 and
p21. Interestingly, the concentration of synovial fluid IL-6 was remarkably elevated in OA patients, and was correlated
with synovial fluid and serum FSTL1 levels.
Conclusions: These findings show that FSTL1 functions as an important proinflammatory factor in the pathogenesis of
OA by activating the canonical NF-κB pathway and enhancing synoviocytes proliferation, suggesting that FSTL1 may
be a promising target for the treatment of OA.Introduction
Osteoarthritis (OA) is a rheumatic disorder with the high-
est prevalence among all arthritis. Knee OA causes to most
of mobility disability in the elderly over 65 [1]. As the deg-
radation of articular cartilage proceeds, OA patients suffer* Correspondence: yujiwang@sohu.com
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ness, stiffness, locking, and sometimes an effusion. Import-
antly, the synovium and cartilage of the OA patients are
often subject to extreme changes of microenvironment
triggered largely by inflammatory cytokines and proteases
in extracellular matrix (ECM), and thus leading to dysfunc-
tion of various types of cell in synovitis joints, especially
fibroblast-like synoviocytes (FLSs) [2,3]. Inflammation of
the synovium is frequently involved in the pathological
process, even in the early stages of OA [4,5]. A growing
body of evidence indicates the importance of activated FLS
in OA pathogenesis. FLS promotes cartilage degradation
through the secretion of inflammatory/catabolic mediatorsis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Characteristics of the subjects investigateda
HC OA
Number 30 58
Age (years)b 60 (55–64) 66 (60–75)
Sex (M/F) 16/14 25/33
Disease duration (years)b - 1.0 (0.5–3.0)
KL grade (0–4) - 0/11/14/23/10
aIncluded all subjects for whom serum samples were available, and all the SF
samples and primary cell lines from OA subjects were available; bexpressed as
the median (25th to 75th percentile). HC, healthy control individual; OA,
osteoarthritis; KL, Kellgren-Lawrence; SF, synovial fluid.
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a good in vitro model for OA pathogenesis and drug target
discovery [6,9].
Among multiple pathways and mediators influencing
the development and persistence of OA, nuclear factor-
kappa B (NF-κB) transcription factor plays a prominent
role [10,11]. The NF-κB family consists of P50 (NF-κB1),
P52 (NF-κB2), P65 (RelA), RelB and C-Rel. NF-κB pro-
tein, a heterodimer of p50 and p65/RelA, is usually se-
questered by inhibitor of kappa B alpha (IκBα) in the
cytosol in the inactive state [12,13], NF-κB can be acti-
vated by proinflammatory cytokines, excessive mechanical
stress and ECM degradation enzymes. Once the NF-κB
signaling cascade is activated, a complete degradation of
IκB following phosphorylation by upstream IκB kinases
(IKKs) allows the translocation of the Rel/P50 homodimer
to the nucleus and subsequently induces gene transcrip-
tion [14,15]. Activated NF-κB boosts the expression of
many inflammation-related cytokines and chemokines,
such as interleukin 6 (IL-6), interleukin 8 (IL-8), adhesion
molecules and matrix-degrading enzymes, and thus re-
gulating inflammation, immune functions and cellular
growth [16,17]. Therefore, NF-κB-activating kinases are
one of the potential therapeutic OA targets [10].
Follistatin-like protein 1 (FSTL1), which was first identi-
fied as a transforming growth factor β1 (TGF-β1)-inducible
protein, is a secreted extracellular glycoprotein containing
a follistatin-like and extracellular calcium-binding domain
[18]. It has been reported that FSTL1 is involved in diverse
biological processes including cell proliferation and differ-
entiation, wound healing, inflammation, skeletal muscle
growth and fibrosis [19-21]. Previous studies revealed a
substantial connection between the FSTL1 level and sever-
ity of rheumatoid arthritis [22,23]. Moreover, our past
work showed that FSTL1 acts as a serum biochemical
marker of OA and reflects the severity of joint damage in
patients [24].
However, the underlying mechanisms by which FSTL1
plays a role in the pathogenesis of OA are poorly under-
stood. In view of the crucial role of FLS in OA progression
[2,11], this study was aimed at investigating the signal
transduction of FSTL1 in cultured OA FLS, and revealing
the potential roles of FSTL1 in OA pathogenesis.
Material and methods
Synovial fluid and serum samples
Serum and synovial fluid (SF) samples were obtained
from 58 OA patients by synovectomy or joint replace-
ment surgery. OA serum and SF samples were obtained
from patients diagnosed with knee OA (of Kellgren-
Lawrence (KL) score 1 to 4 [25]) according to the 1985
criteria of the American Rheumatism Association [26].
The clinical and demographic characteristics of OA pa-
tients and their controls are shown in Table 1. The SFsamples obtained were centrifuged for 5 min at 10,000
rpm to remove the obvious contamination with blood or
debris. A total of 30 serum samples of apparently healthy
individuals diagnosed without alcohol abuse or chronic
drug or other chronic disease or acute illness were in-
cluded as healthy controls (HCs).This study was reviewed
and approved by the ethics committee of Changzhou No.2
People’s Hospital. Informed consent was received from all
patients and controls.
Isolation and culture of human FLSs
Synovial tissue specimens were obtained from OA patients
by synovectomy or joint replacement surgery. Tissues
were carefully minced and digested with 1 mg/ml collage-
nase I (Sigma-Aldrich, St. Louis, MO, USA) in serum-free
Dulbecco’s modified Eagle’s medium (DMEM) (Gibco
BRL, Grand Island, NY, USA) for 4 to 6 hrs at 37°C, fil-
tered through a 70-μm cell strainer (BD, Durham, NC,
USA), extensively washed with DMEM blank and finally
cultured in DMEM supplemented with 10% fetal calf
serum (Gibco BRL, Grand Island, NY, USA), 100 U peni-
cillin, and 100 μg/ml streptomycin in a standard cell cul-
ture chamber containing 5% CO2. The nonadherent cells
were removed next day. The adherent cells were cultured
up to 90% confluence and then split in 1/3 ratio up to pas-
sage 3–6 (consisting of a homogeneous population). The
cultured FLSs at these passages were used for subsequent
experiments.
Reagents and stimulation assays
Each FLS line from an individual OA patient was used
for each experiment, which was repeated two times with
different OA FLS lines. Cultured FLSs were grown in
100-mm cell culture dishes (8 to 10 × 105 cells/dish) for
western blot or in 6-well plates (1 to 1.5 × 105 cells/well)
for mRNA extraction. Cultures were stimulated with hu-
man recombinant FSTL1 (Adipo Bioscience, Santa Clara,
CA, USA), which was dissolved in phosphate-buffered
saline (PBS) solution, or vehicle (PBS solution). Stimula-
tion was applied for 24 or 48 hrs for mRNA extraction,
or for 30 min for NF-κB activation, or 48 hrs for super-
natant collection. BAY 11–7082 (Selleckchem, Houston,
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way, was dissolved in dimethyl sulphoxide (DMSO) solu-
tion to the concentration of 5 mM, and added to the
cultures at ratio of 1:1,000 (final concentration was
5 μM) [27] for 1 hr pretreatment.
Cell proliferation
Cell proliferation assay was performed using a novel
tetrazolium compound (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium,
inner salt; MTS) and an electron coupling reagent (phena-
zine ethosulfate; PES)-based CellTiter 96™ AQueous
One Solution Cell Proliferation (MTS) assay (Promega,
Madison, WI, USA). OA FLSs were seeded at about 2,000
cells per well in 96-well plates in triplicate for 7 days
under regular growth conditions (DMEM with 10% fetal
bovine serum (FBS)), and then MTS cell viability assay
was performed daily according to the manufacturer’s in-
structions. Twelve hours after seeding, FSTL1 was added
daily in the medium, which was changed every two days.
Real-time polymerase chain reaction (PCR)
Total RNA was extracted from cultured FLSs using
NucleoSpin RNA Kit (MN, Düren, Germany) according to
the manufacturer’s instructions. One μg total RNA was
reverse-transcribed using the High-Capacity cDNA Re-
verse Transcription Kit (Applied Biosystems, Foster City,
CA, USA) according to the manufacturer’s instructions. A
quantitative real-time PCR assay was carried out using
SYBR™ Select Master Mix (Applied Biosystems, Austin,
TX, USA) in a Bio-Rad iQ5 (Bio-Rad Laboratories,
Hercules, CA, USA). Primer sequences for amplifying hu-
man cytokines cDNA and internal control glyceraldehyde
3-phosphate dehydrogenase (GAPDH) were as follows: IL-
1β, 5′- AAGCTGAGGAAGATGCTG −3′ (forward) and
5′- ATCTACACTCTCCAGCTG −3′ (reverse); IL-6, 5′-
GAACTCCTTCTCCACAAGCGCCTT −3′ (forward) and
5′- GACCAGTGATGATTTTCACCAGG −3′ (reverse);
TNF-a, 5′- CCAGGCAGTCAGATCATCTTCTC −3′
(forward) and 5′- AGCTGGTTATCTCTCAGCTCCAC −3′
(reverse); GAPDH, 5′-AGGGCTGCTTTTAACTCTGGT-
3′ (forward) and 5′-CCCCACTTGATTTTGGAGGGA-3′
(reverse). The comparative threshold cycle method was
used for relative quantification of mRNA.
Western blot
Cultured FLSs were lysed in RIPA and boiled. Sodium
dodecyl sulfate (SDS)-polyacrylamide gel electrophor-
esis was conducted on 10% polyacrylamide gel and
transferred to polyvinylidene fluoride (PVDF) mem-
brane. Rabbit anti-human p65 polyclonal antibody,
rabbit anti-human phosphate p-65 polyclonal antibody,
rabbit anti-human IκB polyclonal antibody, mouse anti-
human phosphate IκB monoclonal antibody, and rabbitanti-human p50 polyclonal antibody (all these anti-
bodies were purchased from Cell Signaling Technology,
Danvers, MA, USA) were used to detect the corre-
sponding protein in the NF-κB signaling pathway.
Rabbit anti-human actin polyclonal antibody was used
to detect actin signal as an internal loading control and
relative expression levels were quantified by running the
Quantity One software (Bio-Rad Laboratories, Hercules,
CA, USA).
Chromatin immunoprecipitation (ChIP)
Cultured FLSs were subjected to 5 μg/ml FSTL1 or ve-
hicle (PBS solution) for 12 hrs. A total of 107 cells were
fixed and cross-linked in fresh 1% formaldehyde for 10
min and then quenched with 2.5 M glycine for 5 min at
room temperature. Cells were then harvested and sus-
pended in lysis buffer. Simple ChIP™ Enzymatic Chroma-
tin IP Kit (Cell Signaling Technology, Danvers, MA,
USA) was used according to the manufacturer’s instruc-
tions. Chromatin was digested with micrococcal nucle-
ase, sheared by sonication and then lysates were clarified
by centrifugation at 10,000 rpm for 10 min at 4°C. The
supernatant was incubated with ChIP-grade rabbit anti-
human p65 polyclonal antibody (Cell Signaling Technol-
ogy, Danvers, MA, USA) or normal immunoglobulin G
(IgG) overnight at 4°C with rotation. After being pulled
down with protein G agarose beads, the target protein-
DNA complexes were sequentially washed several times
and reverse cross-linked to elute DNA for the subse-
quent experiment. DNA was purified and real-time PCR
was performed to evaluate the ChIP-enriched DNA. Primer
sequences for detecting p65-binding tumor necrosis factor
alpha (TNF-α) promoter region were 5′- ATATGGCCA
CACACTGGGGC −3′ (forward) and 5′- GGGCTTGG
TGGCAGGCTTGA −3′ (reverse). IL-6 promoter region
were 5′- ACCCTCACCCTCCAACAAAG-3′ (forward)
and 5′- GCCTCAGACATCTCCAGTCC −3′ (reverse).
Enzyme-linked immunosorbent assay (ELISA)
TNF-α, interleukin 1β (IL-1β), and IL-6 levels in cell su-
pernatants were measured using a standard quantitative
sandwich ELISA (eBioscience, Vienna, Austria). All ana-
lyses and calibrations were performed in duplicate. Optical
densities were determined using an absorbance microplate
reader (Elx808™ Bio-Tek Instruments, Winooski, VT,
USA) at 450 nm. Gen5 Data Analysis software (Bio-Tek
Instruments, Winooski, VT, USA) was used to analyze all
data and depict the standard curve.
Statistical analysis
Statistical analysis was performed using Prism (Graph-
Pad Software, San Diego, CA, USA) and SPSS 17.0 soft-
ware (SPSS Inc., Chicago, IL, USA). χ2 test was used for
sex difference between OA patients and the controls;
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the associations between serum/SF FSTL1 level and SF
IL-6 level; the significance of other differences was eval-
uated using Student’s t test. P values less than 0.05 were
considered significant.
Results
FSTL1 induces expression and secretion of inflammatory
cytokines from OA FLS
Previous studies showed that FSTL1 expression corre-
lates with severity of arthritis both in OA patients and
mice models [22,24]. And a connection between cyto-
kine/chemokine level and FSTL1 expression has been
established in mice arthritis models [22]. To further
examine FSTL1 functions, we used primary FLSs from
OA patients’ synovial tissues as model cells. First, we in-
cubated FLSs with the two different FSTL1 concentra-
tions (1 μg/ml and 5 μg/ml) for 24 hrs, we observed that
FSTL1 remarkably increased the level of TNF-α , IL-1β
and IL-6 mRNA in the FLSs in a dose-dependent wayFigure 1 FSTL1 increases expression and excretion of inflammatory cytokin
(dissolved in PBS solution) in different concentration (1 μg/ml or 5 μg/ml)
two different durations (24 or 48 hrs). In (A) and (B), total RNA was extracte
IL-6 mRNA were analyzed by real-time PCR. The relative level of mRNA exp
expression, and presented as fold changes relative to the control (the level
the cultures treated with 5 μg/ml FSTL1 for 48 hrs. TNF-α, IL-1β and IL-6 co
as mean ± (standard deviation) SD of three independent experiments (each
*P <0.05, **P <0.01, ***P <0.001, compared to the control (the vehicle-treate
FLS, fibroblast-like synoviocyte; FSTL1, follistatin-like protein 1; IL-1β, interleu
saline; TNF-α, tumor necrosis factor alpha.(Figure 1A). Surprisingly, the increment of IL-6 mRNA
was extremely prominent (more than 200-fold). More-
over, 10 μg/ml FSTL1 treatment did not result in a fur-
ther increase in these mRNA levels compared to the
treatment with 5 μg/ml FSTL1 (data not shown). Next,
FLSs were incubated with 5 μg/ml FSTL1 for two differ-
ent times (24 and 48 hrs).The expression level of the
three inflammatory cytokines increased with the incuba-
tion time (Figure 1B). Consistently, the three secreted
protein levels in the supernatant were markedly elevated
following 48 hrs of treatment with FSTL1 at 5 μg/ml
(Figure 1C-E). Especially, elevation of released IL-6 was
more than 500-fold. Together, these data further support
our previous work that FSTL1 reflects the severity of
OA by promoting the release of inflammatory cytokines
in articular cavity
FSTL1 activates NF-κB signaling in OA FLS
NF-κB signaling is a canonical pathway that participates
in immunity and inflammation [28,29]. Thus we wantedes in cultured OA FLS. (A) Cultured FLSs were treated with FSTL1
for 24 hrs. (B) Cultured FLSs were stimulated with 5 μg/ml FSTL1 for
d and reverse transcribed, and the relative levels of TNF-α, IL-1β and
ression was normalized to the level of housekeeping gene GAPDH
of the control was set as 1). (C-E) Cell supernatant was collected from
ncentrations were measured by ELISA. The above results are presented
FLS line from an individual OA patient was used for each experiment).
d group), Student t test. ELISA, enzyme-linked immunosorbent assay;
kin-1β; IL-6, interleukin-6; OA, osteoarthritis; PBS, phosphate-buffered
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by activation of NF-κB signaling. By western blot
analysis, we found that the level of phosphorylated p65
(p-p65) and phosphorylated IκBα (p-IκBα) in the total
cell lysate were significantly increased following 5 μg/ml
FSTL1 stimulation for 30 min (Figure 2A). In contrast,
the expression of NF-κB subunit p65 and its intracellular
inhibitor IκBα did not show significant changes (Figure 2A).
Next, we separated the contents of the nucleus and carried
out western blot analysis. A marked increase of p-p65, but
not p50/105, was observed in the nucleus (Figure 2B). To
further link NF-κB activation to downstream transcrip-
tional activity, we performed ChIP assay. As compared toFigure 2 FSTL1 activates the NF-κB pathway in FLS. (A) Following treatme
determined by western blot analysis. (B) Nuclear extracts were isolated to f
were treated with FSTL1 (5 μg/ml) or vehicle (PBS solution) for 30 min. Rep
shown for the corresponding groups. The relative protein levels were norm
presented as fold changes relative to the control group (the level of the co
without FSTL1 for 12 hrs, and then ChIP assay targeting the p65 binding si
shown as the percentage of input. The above results are presented as mea
(each FLS cell line from an individual patient was used for each experimen
group, Student t test. ChIP, chromatin immunoprecipitation; FLS, fibroblast-
NF-κB, nuclear factor kappa B; PBS, phosphate-buffered saline; TNF-α, tumothe control, FSTL1 promoted more p65 subunits to bind
to the TNF-α and IL-6 promoter region, suggesting tran-
scription activation of TNF-α and IL-6 (Figure 2C-D). And
the enrichment folds were approximately 1.5 and 8 re-
spectively, in line with the pattern of the mRNA incre-
ments. Next, we utilized BAY 11–7082 (5 μM), an effective
inhibitor of IκBα phosphorylation, to specifically abrogate
NF-κB DNA binding, and eventually downregulate the
NF-κB-inducible cytokine levels. Compared to the control
group, BAY 11–7082 significantly attenuated the FSTL1-
triggered increase in the expression of inflammatory cyto-
kines (Figure 3A-D). And the inhibitor itself did not affect
the baseline level of these cytokines. Taken together,nt, the levels of key components of NF-κB in total cell lysates were
urther confirm the activation of NF-κB pathway. In (A) and (B), FLSs
resentative western blot (Left) and quantification data (Right) are
alized to the level of the internal control, actin or histone 3 (H3), and
ntrol group was set as 1). (C) and (D) FLSs were treated with or
te on TNF-α (C) and IL-6 promoter (D) was performed. Data were
n ± (standard deviation) SD of three independent experiments
t). *P <0.05, **P <0.01, ***P <0.001, compared to the vehicle-treated
like synoviocyte; FSTL1, follistatin-like protein 1; IL-6, interleukin-6;
r necrosis factor alpha.
Figure 3 Inhibition of the NF-κB pathway eliminates the proinflammatory effects of FSTL1. (A) FLSs cultured in a 6-well plate were pretreated
with BAY 11–7082 for 1 hour before addition of FSTL1, and then incubated with FSTL1 or vehicle (PBS solution) for 48 hrs. The relative levels of
TNF-α, IL-1β and IL-6 mRNA were analyzed by real-time PCR as in Figure 1. (B-D) Cell supernatants were collected, and TNF-α, IL-1β and IL-6
concentrations were evaluated by ELISA. All results are presented as mean ± (standard deviation) SD of three independent experiments (each
FLS cell line from an individual patient was used for each experiment). *P <0.05, **P <0.01, ***P <0.001, relative to the control or between groups
as indicated, Student t test. ELISA, enzyme-linked immunosorbent assay; FLS, fibroblast-like synoviocyte; FSTL1, follistatin-like protein 1; IL-1β,
interleukin-1β; IL-6, interleukin-6; NF-κB, nuclear factor kappa B; PBS, phosphate-buffered saline; PCR, polymerase chain reaction; TNF-α, tumor
necrosis factor alpha.
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vating NF-κB signaling in OA FLS.
FSTL1 accelerates the proliferation of FLS in a p53 and
p21 dependent way
Previous work suggests that activation of the NF-κB
signaling pathway is associated with synovial fibroblast
hyperplasia, and thus contributes to OA progression
[30]. Thus, we wondered if FSTL1 promotes the pro-
liferation of FLS. After FLSs were treated with FSTL1
for 6 consecutive days (FSTL1 was daily added to the
medium), an increase of FLS number was significant
in the subsequent 5 days (D3 to 7) as indicated in
Figure 4A. To further examine if the FSTL1-induced
FLS proliferation depends on the expression of two
tumor suppressors: p53 and p21, we carried out west-
ern blot analysis on D4 and D6. As shown in Figure 4B,
FSTL1 significantly inhibited the expression of p53 and
p21 on the two time points (the data from D6 not
shown). Collectively, these results suggest that FSTL1
enhances the proliferation of FLS in a p53- and p21-
dependent way in OA FLS.The elevated level of SF FSTL1 and serum FSTL1
correlates with the increased level of SF IL-6 in OA
patients
As shown earlier, FSTL1 significantly improved expres-
sion and release of three inflammatory cytokines. In
combination with our previous work that both serum
and SF levels of FSTL1 are elevated in OA patients
[24]. First, we tried to compare the concentrations of
these cytokines in serum between OA patients and
HC. By ELISA analysis, the three cytokines (TNF-α,
IL-1β and IL-6) were undetectable in all HC serum
samples. Also, we failed to detect the levels of TNF-α
and IL-1β in OA patients. Intriguingly, we observed a
marked increase of the SF IL-6 level (42.08 ± 73.38 pg/ml)
in 58 OA patients. Next, we analyzed the association
between FSTL1 (SF and serum) and SF IL-6 in 58 OA
patients. As illustrated in Figure 5A-B, the level of SF
IL-6 is significantly associated with SF FSTL1(r = 0.53,
P <0.0001) and also correlated with serum FSTL1 (r =
0.34, P = 0.0086). These data suggest that FSTL1 is
involved in osteoarthritis by elevating inflammatory
cytokine IL-6.
Figure 4 FSTL1 enhances proliferation of FLS in a p53- and p21-dependent way. (A) About 2,000 OA FLS cells per well were seeded into a
96-well plate in triplicate (the seeding day was referred to as Day 0, that is, D0). On the subsequent 6 days (referred as to D1 to D6), 5 μg/ml
FSTL1 was daily applied to the medium. MTS test was performed daily on D2 to D7. (B) Cells were collected after D4 exposure to 5 μg/ml FSTL1
and western blots for p53 and p21 were conducted. Left panel, representative blots; Right panel, quantification data. Results in (A) and (B) are
presented as mean ± (standard deviation) SD of three independent experiments (each FLS cell line from an individual patient was used for each
experiment). *P <0.05, **P <0.01, compared to the vehicle-treated control, Student t test. FLS, fibroblast-like synoviocyte; FSTL1, follistatin-like
protein 1; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; OA, osteoarthritis.
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As a secreted extracellular glycoprotein, FSTL1 is
widely considered to participate in development and
immune diseases pathogenesis. And some groups iden-
tified FSTL1 as a new proinflammatory mediator that
contributes to rheumatoid arthritis by promoting the
expression of TNFα, IL-1β, IL-6 and IL-8, as well as by
enhancing the interferon-γ (IFN-γ) signaling pathway
in a mouse model [22,31,32]. In this study, we observed
two significant effects of FSTL1 in cultured OA FLS.One is that FSTL1 remarkably stimulates the expres-
sion and secretion of proinflammatory cytokines TNF-
α, IL-1β, and especially IL-6 by activating the NF-κB
signaling pathway. Interestingly, there was an associ-
ation between elevated FSTL1 levels and significant in-
creased IL-6 concentrations in SF of OA patients. The
other one is that FSTL1 promotes the proliferation of
FLS in a p53- and p2-dependent way. These findings
further suggest that FSTL1 might be a potential target
for the treatment of OA in humans.
Figure 5 Correlation of SF and serum FSTL1 concentrations with SF
IL-6 concentration in OA patients. (A) The association between
concentrations of IL-6 and FSTL1 in SF of OA patients was evaluated.
(B) The association between concentrations of SF IL-6 and serum
FSTL1 in OA patients was evaluated. Fifty-eight paired samples
(serum versus SF) were collected from 58 OA patients. Correlation
coefficients (r) and P values from the Spearman rank-order test are
shown. Each point represents an individual value. FSTL1, follistatin-like
protein 1; IL-6, interleukin-6; OA, osteoarthritis; SF, synovial fluid.
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inflammatory cytokines related to the pathophysiology
of OA [33]. A number of studies revealed that the func-
tion of TNF-α is involved in activation of the inflamma-
tory cascades and IL-1β is a major player of cartilage
erosion in OA [34-37]. IL-6 is also reported to exert a
proinflammatory role in degenerative joint disease [37].
Importantly, the serum and SF levels of IL-6 are elevated
in OA patients [38,39], consistent with our results.
Moreover, IL-6 attributes to subchondral bone damage
in OA by triggering osteoclast differentiation and boneresorption [40]. Our prior work showed that the level of
increased serum FSTL1 may be identified as a potential
serum marker related to the severity of joint damage of
OA [23]. Taken together, FSTL1-induced IL-6 overex-
pression plays a key role in exaggerating OA progres-
sion. In this study, we further established the correlation
between serum FSTL1 level and IL-6 concentrations in
SF. FSTL1 exerts its proinflammatory role by changing
the microenvironment of synoviocytes and directly
stimulating secretion of inflammatory cytokines by FLS.
To further understand the role of FSTL1 in OA pro-
gression, we aimed to search for its receptor on FLS
membrane. Murakami and his coworkers reported that
a disco-interacting protein 2 homolog a (DIP2a) from
Drosophila was a candidate receptor for FSTL1 in
endothelial cells [39]. It exerted the anti-apoptotic and
promigratory effects of FSTL1 and mediated FSTL1-
induced activation of Akt [41,42]. But so far there are
no reports of the existence of DIP2a in synovium or
FLSs. In our primary FLS culture, only a few of DIP2a-
positive cells were detected by immunohistochemistry
staining. Furthermore, we knocked down of DIP2a with
small interfering RNA (siRNA) (the effectiveness of
knockdown was confirmed in HEK293T cells), but
failed to observe statistically significant alterations in
FSTL1-induced inflammatory cytokines. Therefore, it
seems that the effects of FSTL1 may not be mediated
by DIP2a in OA FLS. There is evidence that FSTL1 can
bind to CD14 and elicits an innate immune response
via Toll-like receptor 4 (TLR4) [43]. In HEK293T,
FSTL1 activates NF-κB and elevates the level of IL-6
and IL-8 [43]. Thus it is likely that in OA FLS, FSTL1
promotes inflammation via the CD14-TLR4 pathway
rather than DIP2a. In addition, we cannot exclude that
the effects of FSTL1 is achieved via the TGF superfam-
ily, since FSTL1 interacts with the TGF-β superfamily,
including activin, TGF-β, bone morphogenetic protein
(BMP)-2⁄4, and their receptors [42,44].
Our results show that FSTL1 activates the NF-κB path-
way upon binding to its unidentified receptor in OA FLS.
We provide evidence that the active transcriptional elem-
ent p65 is recruited to the promoter region of TNF-α and
IL-6, and as a result directly enhances the expression level
of these cytokines. Since TNF-α and IL-1β also can be in-
duced by activation of p38 and c-Jun N-terminal kinase
(JNK) and their downstream transcriptional factor AP1
[45], it may be an explanation of the not fully abolished
level of the cytokines after inhibition of NF-κB signaling
by BAY 11–7082. Furthermore, it was reported that
FSTL1 contributes to arthritis as a proinflammatory medi-
ator by enhancing the IFN-γ signaling pathway in a
collagen-induced arthritis (CIA) mouse model [32]. Overall,
FSTL1 can activate multi-proinflammatory pathways to
participate in OA pathophysiology.
Ni et al. Arthritis Research & Therapy  (2015) 17:91 Page 9 of 10In this study, we also observed that FSTL1 enhances
FLSs proliferation, suggesting that FSTL1 acts as a
synoviopathy-inducing factor to be involved in OA patho-
genesis by the increasing expansiveness of FLS. It is
thought that a pannus formed by abnormal proliferative
FLS is a hallmark of rheumatoid arthritis and OA, finally
damaging articular bone and cartilage [46]. Since p53, a
tumor-suppressor protein, plays a pivotal role in cell cycle
regulation and programmed cell death, we intended to de-
termine whether the overgrowth is due to the inhibition of
its activity in the presence of FSTL1. Our western blot
analysis supported the idea. Supportably, p53 serves as an
intracellular anti-inflammatory function [47]. The absence
of p53 is involved in both decreased apoptosis of FLS and
increased synovial IL-6 production in a CIA mouse model
[48]. p21, a cyclin-dependent kinase inhibitor, is induced
by p53, and participates in the pathogenesis of OA by
blocking of overexpressed IL-6 and matrix metalloprotein-
ases (MMPs) synthesis [49]. Consistently, we also observed
that the application of FSTL1 markedly downregulated the
expression of p21, implicating the involvement of p21 in
the proliferative effects of FSTL1.Therefore, we propose
that FSTL1 exacerbates OA by facilitating expansiveness
of FLS as a synoviopathy-inducing factor besides increas-
ing secretion of inflammatory cytokines. Like many in-
flammatory factors (such as interleukin-17 (IL-17)) [50],
FSTL1 has ‘dual power’ to exacerbate arthritis.Conclusions
FSTL1 significantly promotes the expression of inflam-
matory cytokines (TNF-α, IL-1β and IL-6) in cultured
FLS from OA patients, which is achieved by activating
the NF-κB pathway. Moreover, FSTL1 improves FLS
proliferation in a p53- and p21-dependent pathway.
Finally, the elevated concentration of SF IL-6 is correlated
with serum and SF FSTL1 levels in OA patients. These
findings suggest that FSTL1 is involved in the progression
of synovial inflammation and hyperplasia in OA, and
presumably is a potential target for OA therapy.Abbreviations
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